Saira Ramasastry - 18 Dec 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
Director
Signature
/s/ Jody Howe, Attorney-in-Fact
Issuer symbol
MIRM
Transactions as of
18 Dec 2025
Net transactions value
-$92,440
Form type
4
Filing time
19 Dec 2025, 16:15:46 UTC
Previous filing
07 Nov 2025
Next filing
23 Dec 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ramasastry Saira Director C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY /s/ Jody Howe, Attorney-in-Fact 19 Dec 2025 0001547959

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Options Exercise $47,020 +2,000 $23.51 2,000 18 Dec 2025 Direct
transaction MIRM Common Stock Sale $69,460 -1,000 -50% $69.46 1,000 18 Dec 2025 Direct F1
transaction MIRM Common Stock Sale $70,000 -1,000 -100% $70.00 0 18 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Stock Option (right to buy) Options Exercise $0 -2,000 -12% $0.000000 15,000 18 Dec 2025 Common Stock 2,000 $23.51 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on September 18, 2025.
F2 The stock option is fully vested.